President Trump is preparing to sign an executive order that would expand federal research into ibogaine, a psychedelic drug currently classified as having no medical use and a high potential for abuse.
The order, expected as early as this week, would not reclassify the substance but aims to unlock government funding for studies on its safety and effectiveness, particularly for treating PTSD and traumatic brain injury in veterans.
This move comes despite the administration’s stalled effort to reschedule marijuana, highlighting a selective approach to psychedelic reform that prioritizes certain substances over others based on emerging anecdotal and clinical interest.
Ibogaine, derived from a shrub native to Africa, has been used abroad to treat addiction, depression, and PTSD, but remains illegal in the U.S., prompting Americans to seek treatment in unregulated clinics in Mexico and the Caribbean.
Texas has already committed $50 million to ibogaine research under Governor Greg Abbott, reflecting growing state-level interest in alternative therapies for veterans struggling with opioid dependence and trauma.
Still, the drug carries significant risks: a 2023 review of 24 studies found ibogaine can cause fatal heart rhythm disturbances, with at least 27 deaths linked to its use.
Scientific evidence remains limited — mostly small observational studies and a single completed double-blind trial — leaving researchers cautious about declaring it safe or effective without larger, controlled studies.
Administration officials acknowledge the research is in an early phase and frame the effort as a way to determine whether ibogaine is “snake oil” or a legitimate treatment.
For more on this story, see Trump’s FY 2027 Budget: Rosy Projections and the Growing National Debt.
The executive order would signal a willingness to explore psychedelics within strict federal boundaries, avoiding broader legalization although opening the door to scientifically rigorous evaluation.
This approach contrasts with the administration’s unfulfilled promise to reschedule marijuana, suggesting a narrower, more cautious path toward psychedelic research that avoids political flashpoints.
Veterans advocacy groups have long pushed for access to alternative therapies, and media coverage — including a 2023 “60 Minutes” segment on veterans seeking ibogaine in Mexico — has helped build public awareness of the issue.
Still, the lack of a clear regulatory pathway for medical use means any near-term benefits would remain confined to research settings, not clinical practice.
The administration has not detailed how it will facilitate research funding or oversight, with internal discussions still underway on implementation strategies.
By focusing on ibogaine — a substance with both promise and peril — the order reflects a broader tension in drug policy: balancing innovation in mental health treatment against proven risks and regulatory caution.
This follows our earlier report, Belgium’s Federal Debt Exceeds 550 Billion Euros.
What does the executive order actually do?
The order directs federal agencies to explore funding and research pathways for ibogaine but does not change its legal status or approve it for medical use.
Why is ibogaine being studied now?
Growing anecdotal evidence and state-level initiatives, particularly in Texas, have prompted federal interest in evaluating ibogaine’s potential for treating PTSD and addiction, especially among veterans.
What are the main risks associated with ibogaine?
The most serious risk is cardiac toxicity — ibogaine can trigger dangerous heart rhythms that may be fatal, a concern highlighted in multiple clinical reviews.
How does this relate to the administration’s marijuana policy?
While Trump signed an order to review marijuana rescheduling months ago, that action remains unimplemented; the ibogaine order represents a separate, narrower focus on psychedelic research without broader drug reform.
